Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-19
2008-12-30
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S314000, C514S313000
Reexamination Certificate
active
07470709
ABSTRACT:
Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.
REFERENCES:
patent: 4659657 (1987-04-01), Harnisch et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5414088 (1995-05-01), Von Der Saal et al.
patent: 5585380 (1996-12-01), Bianco et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5801212 (1998-09-01), Okamoto et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5981569 (1999-11-01), App et al.
patent: 6057320 (2000-05-01), Spada et al.
patent: 6137010 (2000-10-01), Joo et al.
patent: 6174912 (2001-01-01), Beck et al.
patent: 6258951 (2001-07-01), Lohmann et al.
patent: 6303600 (2001-10-01), Cox et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6313138 (2001-11-01), Fraley et al.
patent: RE37650 (2002-04-01), Myers et al.
patent: 6420382 (2002-07-01), Fraley et al.
patent: 6479512 (2002-11-01), Fraley et al.
patent: 6593344 (2003-07-01), Biedermann et al.
patent: 6605617 (2003-08-01), Renhowe et al.
patent: 6759417 (2004-07-01), Renhowe et al.
patent: 6762194 (2004-07-01), Renhowe et al.
patent: 6774237 (2004-08-01), Renhowe et al.
patent: 6774327 (2004-08-01), Wong
patent: 6800760 (2004-10-01), Renhowe et al.
patent: 2002/0103230 (2002-08-01), Renhowe et al.
patent: 2002/0107392 (2002-08-01), Renhowe et al.
patent: 2003/0028018 (2003-02-01), Renhowe et al.
patent: 2003/0087854 (2003-05-01), Monia et al.
patent: 2003/0158224 (2003-08-01), Renhowe et al.
patent: 2003/0207883 (2003-11-01), Renhowe et al.
patent: 2004/0220196 (2004-11-01), Hannah et al.
patent: 2005/0261307 (2005-11-01), Cai et al.
patent: 2363459 (1975-06-01), None
patent: 3634066 (1988-04-01), None
patent: 19841985 (2000-03-01), None
patent: 0290153 (1988-11-01), None
patent: 0 509 717 (1992-04-01), None
patent: 0 508 800 (1992-10-01), None
patent: 0 747 771 (1996-12-01), None
patent: 0 797 376 (1997-09-01), None
patent: 0 290 153 (1998-11-01), None
patent: 1 086 705 (2001-03-01), None
patent: P0104752 (2002-07-01), None
patent: 63230687 (1988-09-01), None
patent: 6-9952 (1994-01-01), None
patent: 7-43896 (1995-02-01), None
patent: 8-29973 (1996-02-01), None
patent: 63-258903 (1998-10-01), None
patent: 92/18483 (1992-10-01), None
patent: 92/20642 (1992-11-01), None
patent: 95/15758 (1995-06-01), None
patent: 95/18801 (1995-07-01), None
patent: 97/03069 (1997-01-01), None
patent: 97/34876 (1997-09-01), None
patent: 97/48694 (1997-12-01), None
patent: 98/13350 (1998-04-01), None
patent: 99/10349 (1999-03-01), None
patent: 99/50263 (1999-10-01), None
patent: 99/65897 (1999-12-01), None
patent: WO 00/03990 (2000-01-01), None
patent: WO 00/20400 (2000-04-01), None
patent: 00/27379 (2000-05-01), None
patent: WO 00/58315 (2000-10-01), None
patent: WO 00/71129 (2000-11-01), None
patent: 01/02369 (2001-01-01), None
patent: WO 01/12169 (2001-02-01), None
patent: 01/28993 (2001-04-01), None
patent: 01/29025 (2001-04-01), None
patent: WO 01/28993 (2001-04-01), None
patent: 01/52904 (2001-07-01), None
patent: 01/55114 (2001-08-01), None
patent: 01/62251 (2001-08-01), None
patent: 01/62252 (2001-08-01), None
patent: WO 01/74296 (2001-10-01), None
patent: 02/18383 (2002-03-01), None
patent: 02/22598 (2002-03-01), None
patent: WO 02/18383 (2002-03-01), None
patent: WO 02/22598 (2002-03-01), None
patent: 02/32861 (2002-04-01), None
patent: WO 02/26716 (2002-04-01), None
patent: WO 02/058697 (2002-08-01), None
patent: 03/004488 (2003-01-01), None
patent: WO 03/033472 (2003-04-01), None
patent: WO 03/087095 (2003-10-01), None
patent: WO 2004/018419 (2004-03-01), None
patent: WO 2004/030620 (2004-04-01), None
patent: WO 2004/031401 (2004-04-01), None
patent: WO 2004/043389 (2004-05-01), None
patent: WO 2004/063151 (2004-07-01), None
patent: WO 2004/087153 (2004-10-01), None
patent: WO 2005/046589 (2005-05-01), None
patent: WO 2005/053692 (2005-06-01), None
patent: WO 2006/081445 (2006-08-01), None
Salmon, S. E. et al.,Basic&Clinical Pharmacology, Seventh Edition, edited by B. Katzung, Appleton & Lange, pp. 29, 881-884 (1998).
Milauer, B. et al., “Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant,”Nature, vol. 367, pp. 576-579 (1994); published by Nature Publishing Group.
Pinedo, H. M. et al., “Translational Research: The Role of VEGF in Tumor Angiogenesis,”The Oncologist 2000, vol. 5 (suppl. 1), pp. 1-2 (2000).
McMahon, G., “VEGF Receptor Signaling in Tumor Angiogenesis,”The Oncologist 2000, vol. 5 (suppl. 1), pp. 3-10 (2000).
European Search Report dated Feb. 28, 2006 for EP 05017665.0.
Ukrainets, et al., “Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines,” Tetrahedron Letters, vol. 36, No. 42, 1995, pp. 7747-7748.
Carla Heise, et al., “In vivo Preclinical Evaluation of Tyrosine Kinase Inhibitors with Potent Effects on Tumor Angiogenesis, Growth and Metastasis,” Abstract and presentation material for a presentation at the American Association for Cancer Research meeting held in Apr. 2002.
U.S. Appl. No. 10/644,055, Barsanti, et al., Aug. 2003.
U.S. Appl. No. 10/839,793, Barsanti, et al., May 2004.
U.S. Appl. No. 10/982,543, Cai, et al., Nov. 2004.
Cecil, Textbook of Medicine, 21stEdition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher), Chapter 198, pp. 1060-1074).
International Search Report for PCT/US2005/005316 dated Nov. 28, 2005.
Zetter, B. R., “Angiogenesis and Tumor Metastasis,” Annu. Rev. Med., 1998, vol. 49, pp. 407-424; published by Annual Review Inc.
MSNBC News Services, “Mixed results on new cancer drug,” Nov. 9, 2000.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,”Science, 1997, vol. 278, pp. 1041-1042.
Dermer, G. B., “Another Anniversary for the War on Cancer,”Biotechnology, 1994, vol. 12, p. 320.
Freshney, R. I.,Culture of Animal Cells—A Manual of Basic Technique, 1983, pp. 1-4; published by Alan R. Liss, Inc.
Angiogenesis Foundation, “New Study Shows That Acute Myeloid Leukemia is Angiogenesis-Dependent,” Jan. 4, 2000; www.angio.org
ewsandviews/ archive2000/jan—4—2000.html.
Hussong, J. W. et al., “Evidence of increased angiogenesis in acute myeloid leukemia,”Blood, 2000, vol. 95(1), pp. 309-313; The American Society of Hematology.
Kerbel, R. S., “Tumor Angiogenesis: Past, Present and Near Future,”Carcinogenesis, 2000, vol. 21(3), pp. 505-515; Oxford University Press.
Lundberg, L. G. et al., “Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased Vascularity,”American Journal of Pathology, 2000, vol. 157(1), pp. 15-19.
Dankbar, B. et al., “Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma,”Blood, 2000, vol. 5(8), pp. 2630-2636.
Menzel, T. et al., “Elevated Intracellular Level of Basic Fibroblast Growth Factor Correlates with Stage of Chronic Lymphocytic Leukemia and is Associated With Resistance to Fludarabine,”Blood, 1996, vol. 87(3), pp. 1056-1063.
Gruber, G. et al., “Basic Fibroblast Growth Factor is Expressed in CD19/CD11c-Positive Cells in Hairy Cell Leukemia,”Blood, 1999, vol. 94(3), pp. 1077-1085.
Grand, et al., Targeting FGFR3 in Multiple Myeloma: Inhibiti
Barsanti Paul A.
Bussiere Dirksen
Harrison Stephen D.
Heise Carla C.
Jansen Johanna M.
Foley & Lardner LLP
Meara Joseph P.
Novartis Vaccines and Diagnostics Inc.
Seaman D. Margaret
LandOfFree
Benzimidazole quinolinones and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazole quinolinones and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole quinolinones and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4052396